French HealthTech companies raised €2.3 billion in 2025. Yet only 20% of companies surveyed actually raised funds, half reported difficulties accessing financing, and the average fundraising process took around 10 months from first investor contact to closing.
Even more concerning, 41% reported cash-flow pressure.
Those numbers expose one of the biggest misconceptions in HealthTech fundraising:
The problem is not simply finding investors. The problem is reaching the right investors with the right proof, at the right stage, while preserving enough runway to reach the next commercial milestone.
France does not lack capital.
French HealthTech venture funding actually increased 15% in 2025, from €895 million to €1.028 billion. Three rounds alone exceeded €60 million: Adcytherix raised €105 million, Wandercraft €66 million and Nabla €61 million.
France also has an ecosystem approaching 2,800 HealthTech companies, spanning biotechnology, medical devices and digital health/AI.
And the wider Innovation Santé 2030 plan is backed by €7.5 billion, with more than €1 billion dedicated to strengthening biomedical research alongside initiatives around digital health, market access and industrialisation.
So the contradiction is clear:
Capital exists. Innovation exists. Companies exist.
But capital is becoming increasingly selective.
That is why I built the France HealthTech Investor Matrix.
And, more importantly, why I believe it needs to be used alongside a second system:
Investor intelligence + buyer intelligence.
Because in HealthTech, the evidence that unlocks your next customer can often become the evidence that unlocks your next investor.
Capital-to-Revenue Readiness Dashboard
Test whether your fundraising strategy is aligned with investor fit, evidence, buyer proof, runway, capital mix and the commercial milestones your next round actually needs to unlock.
1. Fundraise + Commercial Context
Use realistic assumptions. The calculator is designed to expose the cost of poor investor fit and weak commercial proof before more founder time and runway are consumed.
2. Score Your Investor-to-Revenue Evidence Stack
Score proof strength, not ambition. Low scores identify where investor conversations may stall even when the underlying technology is strong.
3. Six France HealthTech Capital Routes
The dashboard highlights the route most aligned with the profile and stage you selected. The categories are an operating framework, not rigid investment labels.
4. Founder / Investor Risk Flags
These are the issues most likely to weaken the capital story or signal commercial execution risk.
- Buyer proof is currently the weakest part of the evidence stack.
- Lead/follow sequencing should be tightened before broad outreach.
5. 30-Day Capital-to-Revenue Plan
The action plan updates around the weakest part of your score.
- Map 25 high-fit healthcare buyers and the decision-makers behind them.
- Use buyer conversations to validate budget ownership, procurement requirements and ROI evidence.
- Feed the resulting proof back into the investor narrative before scaling outreach.
Investor fit is stronger when buyer proof is stronger.
The HealthTech Buyer Pipeline Sprint turns the commercial side of the fundraise into a defined target system: 25 priority healthcare buyers plus 15 relevant decision-makers. Use it to move from “the market should buy this” toward evidence about who may buy, who influences the decision, what procurement needs, and what proof should be strengthened before the next investor conversation.
The France HealthTech funding problem is becoming a sequencing problem
France Biotech's 2026 panorama, covering 2025 performance, paints a market that remains innovative but financially demanding.
Only 20% of companies raised money, versus 37% a year earlier. Half reported difficulty securing financing, and fundraising averaged roughly 10 months. At the same time, 58% had received some form of non-dilutive financing.
This should fundamentally change the founder question.
Do not start with:
“Which VCs invest in HealthTech?”
Start with:
“What proof must my company produce next, what type of capital should finance that milestone, and which investor is structurally suited to funding it?”
That produces a completely different capital strategy.
The six capital routes in the France HealthTech Investor Matrix
The matrix separates the ecosystem into six categories because a pre-seed clinical AI startup, a pre-commercial biotech, a CE-marked medical device company and a €10 million-revenue scale-up should not be pursuing capital in the same way.
One important caveat: this is an operating segmentation, not a rigid taxonomy. Several investors span multiple stages and sectors, while some generalist or cross-border funds appear because they can be relevant to French companies.
1. Early-Stage HealthTech VCs
Typical fit
Pre-seed / Seed
Founder relevance
Very high
The matrix includes:
Kurma Partners, Elaia, 360 Capital, Pitchdrive, Serena, XAnge, Seventure Partners, Breega and Newfund.
This is where founders are often selling the future economic value of evidence that has not yet been fully produced.
Consequently, the investment case needs to establish more than technical novelty.
The real chain is:
Unmet need → differentiated solution → capable team → scientific/technical defensibility → initial validation → credible market → next de-risking milestone
At this stage, one of the biggest mistakes is building the pitch almost entirely around the product.
Investors are also trying to understand:
What becomes true after this round that is not true today?
Will the company obtain regulatory clearance?
Complete clinical validation?
Convert pilots into paid deployments?
Build a repeatable sales process?
Enter another geography?
Reach a financing milestone that attracts Series A investors?
Your use of funds should therefore be translated into value-inflection points, not merely salaries and operating expenses.
2. Digital Health & AI Investors
Typical fit
Seed / Series A
Founder relevance
High
The matrix includes:
Cathay Innovation, Elaia, Breega, Frst, Heartcore Capital, XAnge, daphni and Supernova Invest.
This is an especially important category because French digital health is moving from an innovation problem toward an adoption and business-model problem.
France Biotech reports that 76% of digital-health solutions are already commercialised. Around 60% incorporate generative AI, while 39% target healthcare systems. Yet financing, reimbursement access, hospital interoperability and data access remain structural barriers.
That changes what “AI traction” means.
An impressive algorithm is not enough.
A stronger investment case answers:
Who buys it?
Who controls the budget?
Who actually signs?
What workflow does it replace or improve?
How long does deployment take?
What evidence does the hospital require?
What is the economic outcome?
Can implementation be replicated from hospital 1 to hospital 10 without services costs exploding?
For a Seed or Series A digital-health company, I would structure investor proof around:
Clinical utility + workflow fit + buyer proof + economic ROI + adoption + defensibility + regulatory/compliance readiness + scalable distribution
This is precisely where commercialisation becomes part of fundraising.
3. Life Sciences & MedTech Investors
Typical fit
Seed / Series A, with substantial variation by asset maturity
Founder relevance
High
The visual includes:
UI Investissement, Kurma Partners, Andera Partners, Truffle Capital, Sofinnova Partners, Turenne Groupe, Omnes and AdBio Partners.
Here, “traction” cannot be evaluated through SaaS metrics alone.
A biotech company may generate enormous enterprise value before producing commercial revenue.
A MedTech company might have a working product but still face clinical validation, CE marking, reimbursement and procurement hurdles.
France Biotech reported that 53% of MedTech and diagnostic products had reached registration or commercialisation in 2025, up from 49% in 2024. CE-certified products increased from 24% to 28%, while longer MDR timelines continued to delay market access.
The evidence chain becomes:
Science → IP → technical validation → clinical evidence → regulatory pathway → reimbursement/access → manufacturing → commercial adoption
And different investors enter at different points along that chain.
The practical fundraising question
A founder should therefore ask:
Which risk does this investor expect to be retired before investing?
A scientifically oriented investor might accept pre-revenue risk while requiring strong IP and clinical rationale.
A later investor might require regulatory visibility.
A growth-oriented investor may care much more about repeatable commercial adoption.
That is why investor-stage fit is not merely a database filter.
It determines what evidence belongs at the centre of the pitch.
4. Growth & Expansion Capital
Typical fit
Series A / B+ and growth stages
Founder relevance
High once commercial repeatability is emerging
The matrix includes:
Eurazeo, Partech, AXA Venture Partners, InfraVia, Bpifrance, Keensight Capital, Ardian and Tikehau Capital.
The burden of proof changes dramatically here.
The question becomes less:
“Can this technology work?”
and much more:
“Can additional capital predictably generate additional enterprise value?”
Growth investors can look deeper into:
Revenue quality
Retention
Gross margin
Customer concentration
Sales efficiency
Implementation burden
International expansion
Management depth
Cash efficiency
Repeatability
Exit optionality
Internationalisation is particularly relevant.
Nearly three-quarters of French HealthTech companies already on the market directly target international markets, up from around two-thirds in 2024. Among biotech and MedTech companies older than ten years, 42% have overseas subsidiaries, with the US the leading destination.
That means a vague slide saying:
“Next: expand into Europe and the US”
is unlikely to be enough.
Investors need to see:
Market attractiveness → buyer density → reimbursement/procurement route → competitive intensity → localisation burden → entry cost → time-to-revenue → likely return on expansion capital
This is another place where market intelligence directly increases investor readiness.
5. Strategic & Corporate Capital
Typical fit
Pilot → Scale
Founder relevance
Medium overall, potentially extremely high for selected companies
The matrix includes:
Sanofi, Servier, Pierre Fabre, Orange Ventures, MACSF, Mutuelles Impact and MAIF Avenir.
Corporate capital should not be treated as simply another VC cheque.
Potential value can include:
Capital + customers + industry credibility + distribution + technical capabilities + domain expertise + strategic partnership
But this also changes the pitch.
A traditional investor might ask:
Can this company become very valuable?
A corporate investor may additionally ask:
Why is this strategically important to us?
That requires another layer of analysis:
Strategic alignment
Build-versus-partner economics
Complementarity
Integration potential
Distribution leverage
Patient/provider impact
Competitive differentiation
Option value
And this creates an important sequencing insight:
The best path to corporate investment may begin with revenue.
A successful pilot or commercial deployment can sometimes become stronger evidence for a future strategic investment than approaching the corporate venture team with only a deck.
6. Public Funding & Ecosystem Capital
Typical fit
Non-dilutive / Mixed
Founder relevance
Potentially much higher than founders assume
The wider ecosystem mapped includes:
France 2030, Bpifrance, PariSanté Campus, France Biotech, Medicen Paris Region, Lyonbiopôle, Eurasanté, Genopole and Eurobiomed.
This category matters because French founders should not automatically equate fundraising with selling equity.
58% of HealthTech companies surveyed had benefited from non-dilutive funding during the previous 12 months, primarily from regional authorities, Bpifrance or European programmes.
Bpifrance alone allocated €911 million in health-innovation grants during 2025, including €216 million of structural financing and €695 million of directed financing.
This leads to one of the most important questions in HealthTech finance:
Why finance a milestone with expensive equity if an appropriate non-dilutive mechanism can finance some of the same risk?
Not every project will qualify.
But every financing strategy should at least test the possibility.
Stop building VC lists. Build a capital stack.
Suppose a company estimates that it needs €4 million.
The simplistic approach is:
“We need to raise a €4M Series A.”
The better approach is to decompose what that €4 million actually needs to accomplish.
For example:
€800k: clinical evidence
€500k: regulatory work
€400k: integration/product work
€1.0M: commercial team and first deployments
€500k: international market entry
€800k: working capital and runway
Now ask which financing mechanism should fund each component.
Some could require VC.
Some may qualify for non-dilutive support.
Some could potentially be supported by strategic partners.
Some might eventually be financed through customer revenue.
The resulting model becomes:
Equity + grants + strategic capital + customer revenue + ecosystem support
rather than:
VC or nothing.
Why this potentially matters to dilution
Consider a purely illustrative scenario.
A startup needs €2 million and has an €8 million pre-money valuation.
If all €2 million comes from equity:
Post-money valuation = €10M
Investor ownership:
€2M ÷ €10M = 20%
Now imagine €500,000 of eligible activity can instead be funded non-dilutively and the company only needs to raise €1.5 million in equity at the same €8 million pre-money valuation.
Post-money:
€9.5M
Investor ownership:
€1.5M ÷ €9.5M ≈ 15.8%
That is roughly 4.2 percentage points less dilution in this simplified example.
It is not a promise that grants increase valuation or that every company can substitute grant financing for equity.
It simply demonstrates why capital-source selection itself has economic value.
The Investor Fit Calculator: turn investor research into a scoring system
This is where the France HealthTech Investor Fit Calculator becomes useful.
Most founder investor lists contain an important analytical error:
Every investor is treated almost equally.
A spreadsheet may contain 150 names, but perhaps only 15–25 are truly high-priority prospects at this moment.
The calculator should force founders to score investors before committing valuable management time.
I would use six dimensions.
| Investor-fit variable | Suggested weight | Question |
|---|---|---|
| Stage fit | 25% | Does this investor genuinely fund companies at our maturity? |
| Sector/thesis fit | 20% | Does our exact HealthTech category fit the thesis? |
| Evidence readiness | 20% | Do we already possess the proof this investor is likely to require? |
| Ticket/syndicate fit | 15% | Does cheque size and lead/follow behaviour fit the round? |
| Strategic value | 10% | What comes with the capital? |
| Commercial-fit value | 10% | Can this investor materially help customers, market access or scale? |
Investor Fit Score
A simple model is:
Investor Fit Score = Stage + Sector + Evidence + Ticket + Strategic + Commercial Fit
Then segment the pipeline.
80–100: Tier A, immediate priority
65–79: Tier B, strong prospect
50–64: Tier C, contextual / follower opportunity
Below 50: watchlist rather than active founder time
The thresholds should be adjusted to the company.
The important point is not pretending fundraising can be reduced to mathematics.
It is forcing decision discipline.
What is the ROI of an Investor Fit Calculator?
The biggest ROI is not the calculator itself.
It is the bad decisions it prevents.
France's 10-month average fundraising period gives this issue significant economic weight.
There are four main ROI channels.
ROI 1: Founder time saved
Imagine an unscreened list produces 40 low-fit investors.
Suppose each one consumes only:
30 minutes research + 30 minutes outreach/personalisation + 60 minutes meeting/follow-up
That is already:
2 hours × 40 investors = 80 executive hours
That could represent two full working weeks of senior management capacity.
And in reality, serious opportunities often require substantially more effort.
A scoring system does not eliminate fundraising work.
It helps move that work toward prospects with a stronger probability of structural fit.
ROI 2: Runway protected
The second component is more important.
Use this equation:
Fundraising Delay Cost = Monthly Net Burn × Avoidable Delay
For a startup burning €50,000 per month:
1 month = €50,000
2 months = €100,000
3 months = €150,000
The Investor Fit Calculator cannot promise to shorten a fundraise.
But with French HealthTech fundraising averaging around 10 months and 41% of surveyed companies reporting cash-flow pressure, even reducing avoidable targeting mistakes has potentially material value.
This is why I would not market the calculator as:
“Find investors.”
I would position it as:
“Protect runway by prioritising the investors most structurally aligned with your round.”
Much stronger.
ROI 3: Lower avoidable dilution
The third return comes from recognising that equity is not the only financing route.
If the calculator and capital-mapping process identifies:
non-dilutive programmes, strategic financing, customer-financed validation or another appropriate capital source, the size or timing of the equity round may change.
Again, 58% of companies in the France Biotech survey had accessed non-dilutive funding.
That does not mean 58% avoided equity.
It means founders have evidence that a mixed capital model is normal rather than exceptional in this ecosystem.
ROI 4: Better evidence before the investor meeting
This is probably the most important and least discussed return.
An investor score of 90/100 does not matter if the startup cannot answer:
Who will buy?
That brings us to the biggest missing link in the France HealthTech capital ecosystem.
Investor fit without buyer proof is incomplete.
France Biotech reports that 76% of French digital-health products are already commercialised, yet companies continue to struggle with reimbursement, interoperability and hospital-market access.
The French government itself highlighted the problem in April 2026 when launching a France 2030 initiative aimed at helping mature healthcare innovations reach healthcare institutions through public procurement.
The barriers it identified included:
financial constraints, uncertainty around real-world value, complex public purchasing processes and a lack of comparable implementation experience.
Those are not fundraising problems.
They are commercialisation problems that become fundraising problems.
This is where the HealthTech Buyer Pipeline Sprint fits
This is why I would pair the investor matrix with my:
HealthTech Buyer Pipeline Sprint: 25 Buyers + 15 Decision-Makers
The investor matrix answers:
Who might finance the company?
The Buyer Pipeline Sprint attacks the equally important question:
Who can buy the solution and which people influence or control that buying decision?
Put the two together and you get something much more powerful:
Capital Intelligence + Buyer Intelligence
Why 25 buyers can be more useful than another 250 investors
For many post-validation HealthTech companies, I would rather see management understand 25 high-fit healthcare buyers deeply than possess a spreadsheet containing 250 loosely relevant investor names.
Why?
Because targeted buyer intelligence can create the commercial evidence that improves investor conversations:
Buyer conversations → pain validation
Pain validation → sharper positioning
Decision-maker interviews → procurement intelligence
Procurement intelligence → better sales strategy
Pilot interest → commercial signal
Paid pilot → revenue evidence
Renewal / expansion → repeatability evidence
And that evidence flows directly back into fundraising.
The Buyer-to-Investor Evidence Flywheel
This is the system I recommend.
Step 1: Identify the right capital
Use the France Investor Matrix to determine:
VC, specialist life-science capital, digital-health capital, strategic capital, growth capital or non-dilutive funding.
↓
Step 2: Score investor fit
Use the Investor Fit Calculator.
Assess:
Stage → Sector → Evidence → Ticket → Strategic value → Commercial value
↓
Step 3: Identify evidence gaps
For each Tier A investor, ask:
What are they likely to challenge?
Maybe:
Clinical proof.
Regulatory pathway.
Reimbursement.
Market size.
Internationalisation.
Hospital demand.
Sales-cycle risk.
Customer concentration.
↓
Step 4: Map target buyers
This is where the 25-buyer pipeline becomes valuable.
Rather than conducting generic outbound, identify organisations with:
Relevant clinical problem
Budget alignment
Technology need
Transformation initiative
Compatible procurement route
Evidence of buying activity
↓
Step 5: Identify the actual humans
Companies do not buy products.
Buying committees do.
The relevant group could contain:
CIO / CTO
Chief Medical Information Officer
Medical Director
Clinical department head
Innovation lead
Procurement
Digital transformation director
Finance / value-analysis stakeholders
Information security
Data protection
The exact composition depends on the product.
That is why your 15 decision-maker layer is commercially important.
↓
Step 6: Generate buyer evidence
Track:
Replies
Meetings
Problem confirmation
Requests for evidence
Pilot discussions
Procurement requirements
Budget objections
Time-to-decision
Paid contracts
↓
Step 7: Feed the evidence back into fundraising
Instead of telling investors:
“Hospitals need this.”
You want to increasingly be able to say:
“We mapped 25 high-fit buyers, engaged the relevant decision-making functions, identified these recurring procurement requirements, generated X qualified conversations and have Y organisations progressing toward validation/pilot/commercial discussion.”
The numbers must obviously be your actual results.
But that is a materially stronger investment narrative.
The GrowthVybz Capital-to-Revenue Framework
I would structure the full system as:
MARKET → BUYER → PROOF → CAPITAL → SCALE
1. MARKET
Where is commercial opportunity strongest?
Analyse:
Market size, reimbursement environment, procurement structure, hospital concentration, competitive intensity and entry friction.
2. BUYER
Who can actually generate revenue?
Map:
accounts, buying triggers, departments, stakeholders and decision-makers.
3. PROOF
What evidence converts interest into purchase?
Determine:
clinical evidence, economic ROI, workflow benefits, implementation burden and procurement requirements.
4. CAPITAL
Who should finance the next milestone?
Score:
investor stage, thesis, ticket, evidence expectations, strategic value and lead/follow role.
5. SCALE
Which proof needs to become repeatable?
Track:
sales-cycle duration, conversion, implementation, retention, expansion and international replicability.
That creates a closed loop:
Capital funds commercial proof → commercial proof improves investor readiness → stronger capital funds scale → scale produces stronger economics.
A practical Founder Evidence Scorecard
Before raising, I would score the company across eight areas.
| Evidence layer | Question investors eventually ask |
|---|---|
| Problem | Is the pain urgent enough to create budget? |
| Clinical | Does the solution improve a meaningful outcome? |
| Economic | What measurable financial value does it create? |
| Buyer | Who actually buys and who influences the decision? |
| Adoption | Will clinicians/users change behaviour? |
| Regulatory | Is there a credible compliance pathway? |
| Market access | How does reimbursement/procurement work? |
| Scale | Can customer 10 be acquired more efficiently than customer 1? |
This exercise often reveals something important:
Your weakest investor argument may actually be a commercialisation problem.
And that is where my work becomes different from simply supplying an investor database.
How I help founders close the missing gap
I am not positioning GrowthVybz as another source of generic VC lists.
The higher-value work is connecting pieces that founders often manage separately.
1. Investor landscape intelligence
I identify the relevant capital universe by:
Stage, sector, geography, ticket, recent activity, thesis and strategic relevance.
Outcome:
Fewer structurally irrelevant investor conversations.
2. Investor Fit Scoring
I turn the universe into:
Tier A → Tier B → Tier C → Watchlist
rather than handing over a flat spreadsheet.
Outcome:
Founder attention moves toward higher-priority opportunities.
3. Evidence-gap analysis
I compare investor expectations against current company proof.
For example:
Excellent technology
but weak payer economics.
Strong clinical results
but unclear hospital purchasing pathway.
Strong pilots
but no repeatable conversion mechanism.
Good domestic traction
but weak evidence for geographic expansion.
Outcome:
The company knows what needs to be strengthened before burning its best investor introductions.
4. Capital-stack design
I map potential combinations of:
Equity
Non-dilutive funding
Strategic capital
Partnerships
Revenue
Outcome:
Potentially less dependence on one funding channel and a better connection between financing and milestones.
5. Buyer Pipeline Intelligence
Through the:
HealthTech Buyer Pipeline Sprint: 25 Buyers + 15 Decision-Makers
the commercial side can be narrowed to a defined set of priority organisations and stakeholders rather than broad prospecting.
Outcome:
More focused business-development effort and a clearer path toward generating commercial proof.
6. Buyer ROI narrative
Healthcare buyers rarely purchase merely because the technology is interesting.
The case needs to translate innovation into something such as:
Hours saved
Cost avoided
Capacity released
Admissions avoided
Length of stay reduced
Administrative burden reduced
Clinical throughput increased
Diagnostic time reduced
Revenue protected
Risk reduced
I help turn those economics into a buyer-facing ROI case.
Outcome:
The same commercial evidence becomes useful for customers, board discussions and investors.
7. Investor narrative
The story then stops being:
“Here is our technology and TAM.”
It becomes:
Here is the clinical problem. Here are the buyers. Here is what they economically gain. Here is our proof. Here is what prevents scale today. Here is what this capital unlocks. Here is why this particular investor fits that milestone.
That is a much more sophisticated capital story.
The ROI formula founders should actually use
The Investor Fit Calculator should eventually connect to a wider Fundraising Efficiency ROI model:
Value Created = Founder Time Saved + Runway Preserved + Dilution Potentially Avoided + Commercial Evidence Value
And:
ROI = (Value Created − Cost of the Process) ÷ Cost of the Process
Not every variable can be predicted precisely.
But management can model scenarios.
Example: the cost of one unnecessary fundraising month
A company with:
€60,000 monthly burn
and a fundraise delayed by one additional month has consumed:
€60,000 of runway
Two months:
€120,000
Three months:
€180,000
Again, an investor-fit system cannot promise to eliminate those delays.
But given the approximately 10-month average fundraising process documented by France Biotech, reducing avoidable mistakes is economically meaningful.
Example: the cost of low-fit investor outreach
Assume a founder pursues 60 investors.
After proper scoring, only 25 qualify as genuinely strong targets.
That leaves 35 low-fit prospects.
If each ultimately requires an average of only two executive hours across:
research + personalisation + outreach + calls + follow-up
then:
35 × 2 = 70 founder hours
At an illustrative internal opportunity cost of €150 per executive hour:
70 × €150 = €10,500 of management capacity
That figure is not a market statistic.
It is a scenario model founders can replace with their own assumptions.
And it still excludes the biggest cost:
distraction from customers.
That is why fundraising ROI and commercial ROI should be measured together
A founder working 70 unnecessary investor hours is not merely losing 70 hours.
Those hours are no longer being used to:
Meet hospital buyers
Build partnerships
Advance pilots
Analyse reimbursement
Improve clinical evidence
Close revenue
And ironically, those activities could have produced precisely the proof the investor wanted.
This is why my preferred model is:
Do not separate fundraising from commercialization.
A 90-day France HealthTech Capital-to-Revenue operating system
For a company considering a raise within the next 6–18 months, I would structure the work roughly like this.
Phase 1: Capital architecture
Define:
Runway → next milestones → amount required → financing alternatives → target round timing
Phase 2: Investor fit
Build and score:
VCs → specialist funds → growth investors → corporate capital → public/non-dilutive options
Phase 3: Evidence audit
Assess:
Clinical → regulatory → reimbursement → economic → buyer → market → financial → competitive proof
Phase 4: Buyer mapping
Identify the 25 highest-value target organisations rather than building another huge prospect database.
Phase 5: Decision-maker mapping
Identify the 15 people or roles most capable of creating movement inside those accounts.
Phase 6: Commercial validation
Use conversations to identify:
Budget ownership → procurement steps → objections → evidence requirements → deployment barriers
Phase 7: ROI construction
Translate the solution into buyer economics.
Phase 8: Investor narrative
Turn actual buyer and market intelligence into investment evidence.
Phase 9: Investor sequencing
Approach:
high-fit potential leads → strategic specialists → followers → broader pipeline
rather than launching an undifferentiated blast.
Phase 10: Feedback intelligence
Track every rejection and buyer objection.
The question is not simply:
Did they say no?
Ask:
Why?
Then convert recurring objections into evidence work.
The three dashboards I would want the CEO to see
A serious HealthTech management team should ideally be able to view three connected dashboards.
Dashboard 1: Runway
Cash
Net burn
Months remaining
Next financing requirement
Capital milestones
Dashboard 2: Buyers
Target accounts
Decision-makers
Conversations
Qualified opportunities
Pilots
Contracts
Pipeline value
Dashboard 3: Investors
Tier A investors
Introductions
Meetings
Diligence
Objections
Lead interest
Follow-on interest
Expected close
Now the board can immediately see whether the company has a:
fundraising problem, commercial problem, evidence problem or timing problem.
That distinction matters enormously.
What founders should take from the France HealthTech Investor Matrix
Do not optimise for:
Number of investor names.
Optimise for:
Investor fit.
Do not optimise for:
Number of investor meetings.
Optimise for:
High-fit investor conversations.
Do not optimise only for:
Capital raised.
Optimise for:
Capital raised relative to dilution, strategic value and milestone creation.
And do not treat customers as something to pursue after the fundraise.
In many commercial-stage HealthTech businesses, buyers are part of the fundraising evidence itself.
What HealthTech executives should take from it
Executives should connect the capital plan directly to the operating plan.
I would want every board to understand:
Runway → milestones → evidence gaps → buyer pipeline → financing requirement → investor pipeline → dependencies → risk
That is particularly important when 41% of French HealthTech companies report cash-flow pressures and financing problems are already causing some companies to slow commercial expansion, internationalisation, recruitment and R&D.
Capital strategy is therefore not merely the CFO's fundraising project.
It is an enterprise risk-management problem.
What investors should take from it
There is also an important signal for investors.
Compare two management teams.
Team A
“We have a list of 300 investors and are starting outreach.”
Team B
“We mapped 90 possible investors, scored 24 as strong fits, identified six realistic lead candidates, mapped relevant non-dilutive routes, identified our top evidence gaps, and are simultaneously developing buyer validation across 25 target accounts.”
Team B is demonstrating more than good fundraising preparation.
It is showing:
Strategic prioritisation
Capital discipline
Commercial awareness
Resource allocation
Management maturity
Those are qualities investors eventually expect management to apply to their capital.
The full France HealthTech ecosystem represented in the matrix
For reference, these are the organisations represented across the matrix and accompanying framework.
Early-stage HealthTech / venture
Kurma Partners, Elaia, 360 Capital, Pitchdrive, Serena, XAnge, Seventure Partners, Breega, Newfund
Digital Health / AI
Cathay Innovation, Elaia, Breega, Frst, Heartcore Capital, XAnge, daphni, Supernova Invest
Life Sciences / MedTech
UI Investissement, Kurma Partners, Andera Partners, Truffle Capital, Sofinnova Partners, Turenne Groupe, Omnes, AdBio Partners
Growth / Expansion Capital
Eurazeo, Partech, AXA Venture Partners, InfraVia, Bpifrance, Keensight Capital, Ardian, Tikehau Capital
Strategic / Corporate Capital
Sanofi, Servier, Pierre Fabre, Orange Ventures, MACSF, Mutuelles Impact, MAIF Avenir
Public / Ecosystem Capital
France 2030, Bpifrance, PariSanté Campus, France Biotech, Medicen Paris Region, Lyonbiopôle, Eurasanté, Genopole, Eurobiomed
Several naturally overlap because stage, mandate and investment strategy are not mutually exclusive.
For context, industry ranking data also shows substantial investment activity across names in the map: in 2024, Bpifrance led the cited French venture ranking with 111 transactions, while Cathay Innovation, Eurazeo, Elaia, Supernova Invest, Turenne, Seventure Partners, Truffle, Serena and XAnge were among the leading firms by investment activity.
The key missing link: from market map to money
A founder can download investor databases.
A founder can buy lead lists.
A founder can make a pitch deck.
Those are individual assets.
What is harder is connecting them:
Which market? → Which buyers? → Which decision-makers? → Which evidence? → Which investor? → Which capital? → Which milestone? → Which next market?
That is the work I focus on at GrowthVybz.
I help HealthTech founders turn market intelligence into commercial and capital decisions.
Not simply:
“Here are some investors.”
But:
Here are the investors that fit.
Here is why they fit.
Here is what they are likely to need to believe.
Here is the evidence currently missing.
Here are the buyers capable of creating that evidence.
Here are the decision-makers behind those buyers.
Here is the ROI case that makes the commercial proposition stronger.
And here is how those signals can be converted into a stronger fundraising narrative.
That is the connection between:
Market → Revenue → Capital → Scale
France's €7.5B opportunity is not automatically your opportunity
Innovation Santé 2030 provides an unusually substantial policy environment, including €7.5 billion of planned support and programmes around biomedical research, digital health, market access and industrial development.
Bpifrance allocated €911 million in health-innovation grants in 2025.
VC investment increased 15%.
Almost three-quarters of commercial-stage HealthTech companies are targeting international markets.
Yet only one in five surveyed companies raised money, and fundraising averaged roughly ten months.
That combination tells me something important:
France does not primarily need more HealthTech opportunity. Founders need better opportunity selection.
Better investor selection.
Better buyer selection.
Better capital selection.
Better evidence selection.
Better timing.
And that is exactly what the matrix, calculator and buyer-pipeline approach are designed to improve.
Final founder checklist
Before approaching another investor, I would want a founder to be able to answer all ten questions:
- What milestone is this round financing?
- Why does that milestone increase enterprise value?
- Which type of capital best fits it?
- Which investors genuinely invest at this stage?
- Which five are realistic lead candidates?
- What evidence will those investors expect?
- Which evidence is currently missing?
- Which buyers can help produce that proof?
- Who controls the buying decision inside those organisations?
- What measurable buyer ROI can we demonstrate?
If those questions cannot yet be answered, adding another 100 investors to the spreadsheet is unlikely to solve the underlying problem.
Ready to turn the France map into an execution pipeline?
If you are a HealthTech founder or executive preparing for a raise, entering France, expanding internationally or trying to convert validation into repeatable revenue, I can help connect the pieces.
Start with the France HealthTech Investor Matrix + Investor Fit Calculator to understand the capital side.
Then use the:
HealthTech Buyer Pipeline Sprint: 25 Buyers + 15 Decision-Makers
to build the commercial side.
Together, the goal is straightforward:
Fewer low-fit conversations.
More relevant buyers.
Stronger commercial proof.
Better use of runway.
A more credible investor narrative.
Because the expensive question is not:
“How many investors can I contact?”
It is:
